/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. BiotechTV - News
  2. HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."
HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

BiotechTV - News · Sep 15, 2026

GenFit's blood test is key to unlocking the MASH market, enabling patient identification and monitoring for newly approved therapies.

GenFit Funds Its Entire R&D Pipeline with Non-Dilutive Royalty and Commercial Revenue

GenFit operates in a rare position for a biotech company by fully funding its three Phase 2 programs through royalty streams from a partnership with Ipsen and revenue from its commercialized MASH diagnostic. This model avoids shareholder dilution and reduces financial risk, providing significant operational stability.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." thumbnail

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

BiotechTV - News·2 months ago

GenFit CEO Argues MASH Therapeutics Market Cannot Exist Without Non-Invasive Diagnostics

The MASH market's potential can only be unlocked by a scalable, non-invasive diagnostic. Biopsies are not feasible for a 90-million-person potential market. Diagnostics are essential for identifying patients and monitoring the efficacy of expensive new treatments, a key requirement for all stakeholders.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." thumbnail

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

BiotechTV - News·2 months ago

GenFit Treats a US Listing as a Tactical Tool, Delisting and Considering a Return

GenFit's CEO reveals a fluid capital markets strategy. The company delisted from US exchanges due to high costs and low news flow but is now considering a return as its pipeline advances. This demonstrates that a public listing is viewed as a strategic option to be utilized when conditions are optimal, not a permanent necessity.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." thumbnail

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

BiotechTV - News·2 months ago

GenFit's Diagnostic Succeeds by Aligning Incentives for Payers, Pharma, and Patients

The MASH diagnostic's value extends beyond clinical utility. It serves the needs of multiple stakeholders: payers avoid wasting money, drug manufacturers ensure their products reach the right patients, and prescribers make data-driven decisions. This multi-stakeholder alignment is key to its adoption.

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." thumbnail

HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."

BiotechTV - News·2 months ago